DGX vs INTS · P/E 22, rev $9.87B vs $7.7M cap
Quest Diagnostics Incorporated (DGX) versus Intensity Therapeutics, Inc. Common stock (INTS) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Latest reported DGX revenue for 2024-12-31 was $9.87B. Net income was $921.0M. Revenue was up 6.7% from 2023-12-31 to 2024-12-31. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
INTS does not have a complete income-statement cache yet.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. INTS currently screens at market cap $7.7M.
Not investment advice. Open the DGX and INTS stock pages for the full models.
Not investment advice.